| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Stifel analyst Benjamin Burnett downgrades Gracell Biotechnologies (NASDAQ:GRCL) from Buy to Hold and lowers the price targe...
Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceuti...
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary...
Key Takeaways: AstraZeneca will acquire Chinese cell therapy maker Gracell for up to $1.2 billion, representing an 86% premi...
Wells Fargo analyst Yanan Zhu downgrades Gracell Biotechnologies (NASDAQ:GRCL) from Overweight to Equal-Weight and announces...
Piper Sandler analyst Joseph Catanzaro downgrades Gracell Biotechnologies (NASDAQ:GRCL) from Overweight to Neutral and annou...
The CNN Money Fear and Greed index showed an increase in overall market sentiment, while the index remained in the "Extreme...
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow...
